CauleyJAZmudaJMEnsrudKEStudy of Osteoporotic Fractures Research Group. Timing of estrogen replacement therapy for optimal osteoporosis prevention. J Clin Endocrinol Metab2001;86:5700–5.
2.
GrodsteinFMansonJEColditzGAA prospective observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med2000;133:933–41.
3.
ZandiP PCarlsonMCPlassmanBLCache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA2002;288:2123–9.
4.
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet1997; 350(9084):1047–59.
5.
DepypereHTTummersPDe BacquerDNumber of women needed in a prospective trial to prove potential cardiovascular benefit of hormone replacement therapy. Climacteric2007;10:238–43.
6.
Writing group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA2002;288:321–33.
7.
The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701–12.
8.
MackWJSlaterCCXiangMElevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. Fertil Steril2004;82(2):391–7.
9.
NedrowAMillerJWalkerMComplementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. Arch Intern Med2006;166(14):1453–65.
10.
HulleySGradyDBushT, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605–13.
11.
HulleySBGradyD. The WHI Estrogen-alone Trial — do things look any better?JAMA2004;291(14):1769–71.
12.
ReidRL. Translating the latest scientific advances into clinical practice — the Women's Health Initiative Study. Evidence-based Obstet Gynecol2002:4 (3):110–1.
13.
NaftolinFTaylorHSKarasRThe Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril2004;81:1498–501.
14.
Utian WH. NIH and WHI — time for a mea culpa and steps beyond. Menopause2007;14 (6):1056–9.
15.
HodisHWMackWJ. Postmenopausal hormone therapy in clinical perspective. Menopause2007;14(5):944–57.
16.
RossouwJPrenticeRLMansonJEPostmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77.
17.
SalpeterSRChengJThabaneLBayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med2009;122:1016–22.
18.
MansonJEAllisonMARossouwJEstrogen therapy and coronary-artery calcification. N Engl J Med2007;356:2591–602.
19.
AllisonMAMansonJELangerRD, for the WHI. Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study. Menopause2008;15(4):639–47.
20.
PhillipsLSLangerRD. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril2005;83:558.
21.
FletcherSWElmoreJG. Clinical practice: mammographic screening for breast cancer. N Engl J Med2003; 348 (17):1672–80.
22.
SingletarySE. Rating the risk factors for breast cancer. Ann Surg2003;237:474–82.
